Prota Therapeutics is developing oral immunotherapy treatments specifically targeting peanut allergies in children, utilizing a proprietary formulation based on over two decades of research. Their lead product, PRT120, aims to provide long-lasting tolerance to peanut allergens, significantly improving the quality of life for affected patients.
Funding
$49.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Peanut allergies pose a significant health risk to children, with potentially life-threatening reactions and a need for constant vigilance. Current management strategies often involve strict avoidance and emergency medication, which can be stressful and limit a child's quality of life. Existing treatments may not provide long-lasting protection or be suitable for all patients.
Solution
Prota Therapeutics is developing PRT120, an oral immunotherapy designed to induce long-lasting tolerance to peanut allergens in children. This investigational treatment aims to desensitize patients to peanuts, reducing the risk of severe allergic reactions and improving their overall quality of life. PRT120 is based on over two decades of research and is currently in late-stage clinical development. The therapy seeks to provide a more proactive and sustainable approach to managing peanut allergies compared to strict avoidance and emergency interventions.
Target Audience
The primary target audience is children with peanut allergies and their families, as well as allergists and pediatricians specializing in food allergy management.
Features
- Oral immunotherapy formulation specifically targeting peanut allergens
- Designed to induce long-lasting tolerance to peanuts
- Currently in late-stage clinical development (Phase 3 ready)
- Aims to reduce the risk of severe allergic reactions
- Intended to improve the quality of life for children with peanut allergies